Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
News
Recent Posts
- Motor neuron diseases are on the increase in Europe, study finds
- Masitinib linked to higher 5-year survival rate in ALS trial
- Neurosense, Health Canada discuss approval path for PrimeC
- What holding on looks like after 16 years of living with ALS
- Study links missing enzyme to early brain damage in ALS